CJC-1295 (No DAC)

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), studied in research settings for its role in stimulating natural growth hormone signaling pathways. In simple terms, it is used in laboratory research to better understand how the body regulates growth hormone release, and how extending that signaling may influence downstream metabolic and cellular …

$40.00

CJC-1295 (No DAC) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) studied in research settings for its role in stimulating endogenous growth hormone secretion through pituitary signaling pathways. In simple terms, researchers use this compound to better understand how natural growth hormone pulses are regulated in the body, and how short-acting GHRH analogs interact with endocrine feedback systems in controlled laboratory models.

From a technical standpoint, CJC-1295 (No DAC) is a 29-amino-acid modified peptide that functions as a GHRH receptor agonist. Unlike the DAC (Drug Affinity Complex) version, this variant does not bind to serum albumin, resulting in a significantly shorter half-life and a more transient pharmacokinetic profile. This allows it to more closely mimic the natural pulsatile secretion pattern of endogenous GHRH in research models, making it useful for studying acute pituitary growth hormone release dynamics.

In preclinical and clinical research environments, CJC-1295 (No DAC) is often evaluated in combination studies involving other growth hormone secretagogues to observe interactions within the somatotropic axis, including downstream IGF-1 signaling pathways, endocrine feedback loops, and metabolic regulation mechanisms. Its effects are strictly dependent on research context, model type, and experimental design.

CJC-1295 (No DAC) is intended strictly for laboratory research purposes only and is not approved for human consumption, medical use, or diagnostic applications.

Key Research Areas

  • Growth hormone-releasing hormone (GHRH) receptor activation
  • Pituitary growth hormone secretion pathways
  • IGF-1 signaling and endocrine axis research
  • Somatotropic axis modulation studies
  • Long-acting peptide pharmacokinetics (CJC-1295 DAC variant)

Chemical Information

  • Compound Name: CJC-1295
  • Type: Synthetic GHRH analog peptide
  • Variants: With DAC / Without DAC
  • Mechanism: Growth hormone-releasing hormone receptor agonist
  • Research Focus: Endocrine and metabolic signaling pathways
  • Half-life: Extended in DAC-modified version (albumin binding)

Important Notice

This compound is sold strictly for laboratory research purposes only. It is not intended for human consumption, medical treatment, or diagnostic use. Proper handling and regulatory compliance are required by the purchaser.

Additional information